Millennium Management
TPTX

Millennium Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Millennium Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-610,489
Closed -$45.9M – 7815
2022
Q2 		$45.9M Buy
610,489
+489,712
+405% +$21.8M 0.03% 704
2022
Q1 		$3.24M Buy
120,777
+76,130
+171% +$2.56M ﹤0.01% 3423
2021
Q4 		$2.13M Buy
44,647
+33,479
+300% +$1.5M ﹤0.01% 3718
2021
Q3 		$742K Buy
11,168
+1,605
+17% +$114K ﹤0.01% 4969
2021
Q2 		$746K Sell
9,563
-55,719
-85% -$4.12M ﹤0.01% 4940
2021
Q1 		$6.17M Buy
65,282
+55,740
+584% +$6.63M ﹤0.01% 2352
2020
Q4 		$1.16M Sell
9,542
-9,458
-50% -$1.04M ﹤0.01% 3632
2020
Q3 		$1.66K Sell
19,000
-83,647
-81% -$5.83M ﹤0.01% 2739
2020
Q2 		$6.63M Buy
+102,647
New +$5.92M 0.01% 1529
2020
Q1 		– Sell
-83,589
Closed -$5.21M – 4739
2019
Q4 		$5.21M Sell
83,589
-193,658
-70% -$9.21M 0.01% 1893
2019
Q3 		$10.4M Buy
+277,247
New +$12.1M 0.02% 1257

Millennium Management's TPTX Position: Q3 2022 in Review

Millennium Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 610,489 shares — an estimated $45.9M sold.

Millennium Management first reported a position in TPTX in Q3 2019 and held it in 11 quarters. The position peaked at $45.9M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Millennium Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Millennium Management sold 610,489 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $45.9M.
  • Millennium Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
  • Millennium Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $45.9M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.